Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion type Assertion NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_head.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion description "[Sustained activation, overexpression, or mutation of the MET pathway is associated with a poor prognosis in a variety of tumors, including non-small cell lung cancer (NSCLC), implicating the MET pathway as a potential therapeutic target for lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion evidence source_evidence_literature NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion SIO_000772 23989980 NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion wasDerivedFrom befree-2016 NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.
- NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_assertion wasGeneratedBy ECO_0000203 NP1106392.RAxj9H_kxrKrxtQ95MA4f3tgESORTZ1nLRUDKi5SNjASM130_provenance.